Background
==========

Allele-specific gene expression is an integral component of cellular programming and development and contributes to the diversity of cellular phenotypes \[[@B1],[@B2]\]. Allelic differences in gene expression are mediated by either parent-of-origin-specific selection (imprinting) or stochastic selection of alleles for activation and/or silencing. The importance of genomic imprinting has recently been highlighted by RNA sequencing studies that demonstrated widespread allelic differences in gene expression in mouse brain affecting more than 1,300 genes \[[@B3]\]. The extent of sex- and stage-specific expression of individual alleles emphasizes the essential role of allelic transcriptional regulation in development. In addition to the extensive occurrence of imprinted parent-of-origin-specific expression, gene expression patterns of clonal cell populations are also modified by random or stochastic silencing of either the maternal or paternal allele. Well-known loci displaying allele-specific expression include odorant receptor genes, immunoglobulins and various receptor proteins \[[@B4]-[@B6]\]. Additionally, previous large-scale studies have provided new data demonstrating that parent-of-origin-specific expression is employed much more frequently than previously thought \[[@B7]\]. These new findings illustrate the scale and complexity of genomic allele-specific expression. However, the precise molecular mechanism underlying the allelic bias in gene expression is not very well understood.

The best-characterized locus with strict monoallelic imprinted gene expression is the region containing the insulin-like growth factor 2 (*IGF2*) and *H19*genes \[[@B8]\]. The regulation of this locus relies on the imprinting control region (ICR), which acquires DNA methylation on the paternal allele during normal development of the male germline. Methylation of cytosines at the ICR inhibits binding of the zinc finger protein CTCF to the paternal allele, preventing its role as an insulator and allowing long-range interactions of the *IGF2*promoter with enhancer elements downstream of the *H19*gene \[[@B9]-[@B11]\]. In contrast, the unmethylated ICR on the maternal allele recruits CTCF, effectively preventing promoter-enhancer interactions and maintaining repression of the maternal *IGF2*gene.

The well-documented requirement of CTCF for imprinted expression at the *IGF2*/*H19*gene locus is thought to result from its role in establishing and/or maintaining long-distance interactions between regulatory elements \[[@B12]\]. Allele-specific binding of CTCF to the ICR has long been known to be essential for the formation of chromatin loops. While the precise mechanism of CTCF\'s role in long-distance chromatin interactions remains unknown, several studies have provided a rationale for the differential expression of the maternal and paternal *IGF2*gene by revealing an interaction of CTCF with cohesin, a protein complex known for its requirement during sister chromatid cohesion in mitosis \[[@B13]-[@B16]\]. Chromosome conformation capture experiments in combination with RNA interference assays recently confirmed the CTCF and cohesin-dependent formation of higher-order chromatin structures at the *IGF2*/*H19*and other gene loci \[[@B17]-[@B19]\].

In addition to DNA methylation, histone modifications also contribute to the maintenance of allele-specific expression. DNA methylation of ICRs is accompanied by repressive histone markers, including histone H3 trimethylated at lysine 9 (H3K9me3). In contrast, the unmethylated allele is characterized by permissive histone markers, including histone H3 trimethylated at lysine 4 \[[@B20]\]. Colocalization of epigenetic markers including DNA methylation and histone H3 dimethylated at lysine 9 has been exploited to identify epigenetically distinct parental alleles. Chromosomal regions displaying overlaps of euchromatin and heterochromatin-specific markers have been enriched for known imprinted genes \[[@B21]\].

Despite the importance of monoallelic expression in cellular development and differentiation, little is known about the establishment and maintenance of random monoallelic expression. The link between allele-specific binding of CTCF and monoallelic expression of the *IGF2*gene prompted us to test whether the presence of CTCF and H3K9me3 specifies a chromatin arrangement which demarcates random monoallelically expressed alleles. Using array-based chromatin immunoprecipitation (ChIP-chip), we identified 293 loci displaying these chromatin markers. We selected the *IGF2BP1*gene locus to further examine whether the presence of CTCF and H3K9me3 comprises a necessary chromatin arrangement for a specific expression profile analogous to the monoallelic behavior observed at the *IGF2*/*H19*locus. Surprisingly, colocalization of CTCF and H3K9me3 does not provide a reliable measure of monoallelic binding of CTCF at the *IGF2BP1*gene. Our studies included allele-specific sequencing of immunoprecipitated chromatin to demonstrate that chromatin at each *IGF2BP1*allele is bivalent. Importantly, both alleles recruit RNA polymerase II, suggesting that silencing of one *IGF2BP1*allele occurs after transcription initiation. By establishing which epigenetic configurations are involved in governing monoallelic gene expression, we will broaden the understanding of epigenetic mechanisms as they relate to cancer progression and cellular differentiation.

Results
=======

Colocalization of CTCF and H3K9me3 in the human genome
------------------------------------------------------

Allele-specific binding of CTCF to the ICR regulates parent-of-origin-specific expression of the *IGF2*gene and correlates with differential cytosine methylation and the presence of H3K9me3 \[[@B9]-[@B11]\]. We carried out a large-scale survey to identify genomic sites with chromatin markers similar to those at the ICR of the *IGF2*/*H19*locus. Using ChIP-chip, we identified CTCF binding sites by tiling through the nonrepetitive portion of the genome in 100-bp intervals. Genomic sites bound by CTCF were assembled on a condensed array set that tiled through 9,823 sites using overlapping probes, and replicate ChIP experiments were performed. By using conservative criteria (positive signal in three replicates; *P*\< 0.05) in this analysis, we identified 8,462 loci that interact with CTCF. To identify the subset of sites that associate with both CTCF and H3K9me3, we tested the association of these 8,462 loci with H3K9me3 using the condensed DNA array set. These analyses revealed 293 loci that are both bound by CTCF and marked by H3K9me3 (Table S1 in Additional file [1](#S1){ref-type="supplementary-material"}) (distances of CTCF and H3K9me3 peaks \< 500 bp). Of the 293 loci, 115 directly mapped to coding regions. Of the remaining loci (174 of 293), the majority (147 loci) were located in intergenic regions at a distance \> 10 kb to the nearest 5\' end of known genes. Only 27 loci mapped to promoter regions. Overall, 40% of the CTCF/H3K9me3 loci mapped to intergenic regions, 51% mapped to intragenic domains and 9% mapped to promoter regions, a distribution similar to that of the 8,462 CTCF loci (44%, 51% and 10% respectively). Notably, the CTCF-regulated *IGF2*/*H19*locus is included in the subset of 293 loci (Figure S1 in Additional file [2](#S2){ref-type="supplementary-material"}), suggesting that our experimental approach may be useful for the identification of similarly expressed genes.

*IGF2BP1*alleles are stochastically expressed in human B cells
--------------------------------------------------------------

Genes classified as \"monoallelically expressed\" encompass both imprinted genes, such as the *IGF2*gene, where monoallelic expression is regulated in a parent-of-origin-specific manner, and stochastic loci, where individual alleles are randomly selected for expression independent of parental origin. In recent studies in which allele-specific transcription was assessed in several human cell lines, more than 300 (7.5%) of 4,000 human genes examined were subject to random monoallelic expression, with a majority of the latter being capable of biallelic expression \[[@B7]\].

To examine whether CTCF binding at sites marked by H3K9me3 is indicative of monoallelic expression, we first compared the genomic positions of our 293 loci with the list of genes expressed in a random allele-specific manner. Only a small number of genes (8 of 293 loci) were common to both the monoallelically expressed cohort described by Gimelbrant *et al*. \[[@B7]\] and our CTCF/H3K9me3 set of ChIP-chip binding loci.

To further examine the correlation between CTCF/H3K9me3 and monoallelic expression, we selected 12 genes located near one of the 293 CTCF/H3K9me3 sites (*DIAPH1*, *FUS1*, *PKP1*, *ARFGAP2*, *PCDHGA*, *MTHFR*, *LAIR1*, *GPR3*, *ARMET*, *NPR1*, *NHLRC1*and *IGF2BP1*) to search lymphoblastoid cell lines (LCLs) derived from a pedigree from the Center d\'Etude du Polymorphisme Humaine (CEPH) for SNPs in exonic and 3\'-UTR regions. The monoclonality of LCLs was confirmed by analysis of their immunoglobulin heavy chain (IgH) gene rearrangement (Figure S2 in Additional file [2](#S2){ref-type="supplementary-material"}) \[[@B22]\]. Sequencing of genomic DNA (gDNA) and cDNA of LCLs identified the insulin-like growth factor binding protein gene *IGF2BP1*as the only candidate gene expressed from only one allele (Table S2 in Additional file [1](#S1){ref-type="supplementary-material"}). *IGF2BP1*is an RNA-binding protein that regulates transcript stability and translation of the imprinted *IGF2*gene \[[@B23]\]. In addition, *IGF2BP1*binds to H19, MYC and β-TrCP1 mRNA to regulate message half-life, localization and translation of RNA, suggesting that the regulation of *IGF2BP1*expression may affect disease and development \[[@B24],[@B25]\]. We focused on *IGF2BP1*to examine the contribution of CTCF and H3K9me3 markers colocalized at intron 5 to allele-specific expression (Figure [1](#F1){ref-type="fig"}).

![**Colocalization of CTCF and H3K9me3 at the *IGF2BP1*locus**. Array-based chromatin immunoprecipitation (ChIP-chip) data for both CTCF and histone H3 trimethylated at lysine 9 (H3K9me3) identify candidate loci for analysis of monoallelic expression. **(A)**Depiction of the *IGF2BP1*gene with specific SNPs examined in this study (arrows). **(B)**Close-up portion of the locus with tracks for CTCF enrichment (top track) and H3K9me3 association (bottom track) near SNP site rs11870560. The ChIP-chip data are displayed using the UCSC Genome Browser. DNA derived from CTCF ChIP experiments was analyzed by using microarrays with hybridization probes spaced 100 bp apart. The higher resolution of the H3K9me3 ChIP-chip data is due to the use of condensed array sets that tiled through all of the CTCF-positive regions with probes overlapping each other by 12 nt.](1756-8935-4-14-1){#F1}

Sequencing of gDNA identified 10 individuals that were heterozygous at SNP rs11655950 in the 3\'-UTR of *IGF2BP1*(Figure [2A](#F2){ref-type="fig"}). All heterozygous SNPs were subsequently typed in cDNA. A comparison of the transcriptome-derived genotypes to genomic genotypes indicated that six individuals expressed *IGF2BP1*primarily from only one allele. In contrast, four individuals were found to express both *IGF2BP1*alleles (Figure [2A](#F2){ref-type="fig"}). SNP determination for genomic and cDNA for CEPH family 1331 was confirmed by allelic discrimination assays based on fluorogenic probes (TaqMan allelic discrimination assay; Applied Biosystems, Foster City, CA, USA), which yielded identical results (Figure S3 in Additional file [2](#S2){ref-type="supplementary-material"}). The TaqMan allelic discrimination assay, a real-time PCR based approach, yields a scatterplot of genotypes capable of quantitatively detecting a range of 1:1 and 1:5 ratios of individual alleles in DNA mixtures at SNP rs11655950 (Figure S4 in Additional file [2](#S2){ref-type="supplementary-material"}). Individuals GM7033 and GM6989 were found to express the paternally inherited *IGF2BP1*allele, while GM7030 and GM7005 were found to express the maternally inherited allele (Figure [2](#F2){ref-type="fig"}). Individuals GM7007 and GM7016 also exhibited monoallelic expression of *IGF2BP1*, but we were unable to identify the mode of expression because of the limited pedigree. These data indicate that monoallelic expression at the *IGF2BP1*gene locus is not determined by parent-of-origin markings; instead, it is defined by stochastic choice.

![**Analysis of allele-specific *IGF2BP1*expression**. Comparative analysis of sequence variations in B lymphoblasts of the CEPH pedigree family 1331 reveals monoallelic expression of the *IGF2BP1*gene. **(A)**Pedigree analysis was carried out for the SNP site rs11655950 located in the 3\'-UTR of the *IGF2BP1*gene. Each individual is shown with CEPH family identification, sample identification and genetic information (SNP genomic DNA (gDNA) genotype- or transcript-derived genotype). Individuals with monoallelic *IGF2BP1*gene expression are indicated by asterisks. If the individual is homozygous at the SNP, allele-specific expression cannot be defined. **(B)**Left: Genotyping results at rs11655950 with gDNA from members of CEPH family 1331. gDNA was analyzed using the TaqMan SNP Genotyping Assay. This assay discriminates between sequence variants using two allele-specific probes carrying two different fluorophores, VIC and FAM. Individuals coded in red and green represent cell lines that are homozygous for alleles A and G, respectively. Orange-labeled individuals contain both A and G alleles at SNP rs11655950 and represent informative cell lines used for further analysis of monoallelic expression. Diamonds indicate cDNA samples, and black × indicates averaged triplicates of a no-template control (NTC) near the origin of the graph. Right: Genotyping results of transcript-derived cDNA from heterozygous B lymphoblasts. Individuals are color-coded in the figure key. No-RT controls (No RT) from cDNA synthesis are shown near the origin of the graph and are indicated by a black X. Control samples (standards) of stem cell lines previously genotyped as homozygous AA, heterozygous AG and homozygous GG were plotted and are indicated by diamonds.](1756-8935-4-14-2){#F2}

CTCF binds to its target motif at the *IGF2BP1*locus independently of DNA methylation
-------------------------------------------------------------------------------------

Binding of CTCF to its target motifs at both the human and mouse ICR of the *IGF2*/*H19*locus is sensitive to DNA methylation \[[@B10],[@B26]\]. To test whether monoallelic expression of *IGF2BP1*in some individuals is also regulated by monoallelic DNA methylation of CTCF binding motifs, we examined a role for CpG methylation and allele-specific binding of CTCF at this locus.

To precisely determine the DNA sequence required for CTCF binding at the *IGF2BP1*locus, we searched for potential motifs using SOMBRERO \[[@B27]\], a *de novo*motif-finding algorithm that uses multiple self-organizing maps (SOM) to cluster sequences of a specific length (reads) from a set of input sequences (such as enriched genomic loci identified by ChIP-chip experiments). Motif alignment using STAMP \[[@B28]\] and comparison to the JASPAR transcription factor database \[[@B29]\] identified a distinct cohort of 68 motif models, all of which were identical to the canonical CTCF motif previously reported (Figure S5 in Additional file [2](#S2){ref-type="supplementary-material"}) \[[@B30]\]. The clustered reads associated with all 68 motif models were mapped back to sequences enriched in our ChIP-chip analysis and were displayed using the UCSC Genome Browser (Figure S6 in Additional file [2](#S2){ref-type="supplementary-material"}). Using this approach, we identified 28,713 peaks, each composed of multiple overlapping reads, within the original 8,462 ChIP-chip loci. Using a strategy similar to that used to study ChIP-seq clustering \[[@B31]\], our frequency analysis of these peak heights yielded a bimodal distribution with an evident power law at low peak heights deviating to a clear excess in the numbers of peaks with heights \> 10 (Figure S7 in Additional file [2](#S2){ref-type="supplementary-material"}). We consequently partitioned the peak populations into low-confidence and high-confidence groups using the peak height threshold of 10 (Figure S8 in Additional file [2](#S2){ref-type="supplementary-material"}).

Using this approach, we identified three potential motifs (X, Y and Z) (Figure [3](#F3){ref-type="fig"}) within the 350-bp region of the *IGF2BP1*gene locus enriched in our ChIP-chip experiments. Two of the putative binding sites, Y and Z, accumulated a significant number of matches to motif models. However, only one of the three putative CTCF binding sites belongs to the group of high-confidence binding sites (site Y) (Figure [3](#F3){ref-type="fig"}). In support of our *in silico*analysis of CTCF binding, previously published high-resolution ChIP-seq data on CTCF binding revealed enrichment of sequences surrounding motifs Y and Z (Figure [3A](#F3){ref-type="fig"}), suggesting that either one or both motifs is required for CTCF recruitment.

![**Functional CTCF sequence motifs at the intronic region of the *IGF2BP1*gene**. **(A)**UCSC Genome Browser display of relative positions of high- and low-confidence CTCF target motifs, ChIP-chip, ChIP sequencing (ChIP-seq) and ChIP self-organizing maps results. **(B)**Y^wt^105-bp and Y^wt^Z^wt^125-bp templates employed in the immobilized template assay. Detailed sequences of the templates are shown in Figure S9 in Additional file [2](#S2){ref-type="supplementary-material"}. **(C)**Western blot analysis of CTCF recruitment to Y^wt^105-bp and Y^wt^Z^wt^125-bp templates containing combinations of wild-type and mutated CTCF target sequences. Motif Y is sufficient for recruitment of CTCF.](1756-8935-4-14-3){#F3}

To further define the contribution of motifs Y and Z to CTCF binding, we measured their ability to recruit CTCF *in vitro*using immobilized template assays (Figures [3B](#F3){ref-type="fig"} and [3C](#F3){ref-type="fig"}). Wild-type and mutant DNA templates containing either one or both motifs were linked to magnetic beads, incubated with nuclear extract, washed and tested for association with CTCF by performing Western blot analysis. A 105-bp template containing the wild-type *IGF2BP1*intronic sequence efficiently recruited CTCF (Y^wt^105-bp template) (Figure [3B](#F3){ref-type="fig"}). In contrast, CTCF binding was severely reduced when the putative CTCF motif Y was mutated by four base substitutions (Figure [3C](#F3){ref-type="fig"} and Figure S9 in Additional file [2](#S2){ref-type="supplementary-material"}). To test the contribution of the adjacent motif Z to CTCF binding at the *IGF2BP1*locus, we generated several 125-bp DNA templates that encompassed both CTCF target motifs (Figure [3B](#F3){ref-type="fig"}). Targeted mutations at specific positions of motif Y and/or motif Z were introduced to test the contribution of each motif to recruitment of CTCF. Detailed sequences are shown in Figure S9 in Additional file [2](#S2){ref-type="supplementary-material"}. As shown in Figure [3C](#F3){ref-type="fig"}, the 125-bp template recruited CTCF more efficiently than the 105-bp template. However, motif Z does not contribute to CTCF recruitment, since targeted mutations in motif Z do not influence the level of CTCF binding. Consistent with this notion, CTCF binding is undetectable in the absence of a wild-type motif Y (Figure [3C](#F3){ref-type="fig"}).

CTCF binding site Y at the *IGF2BP1*gene contains a single CpG residue adjacent to the 14-bp core sequence of CTCF (Figure [4A](#F4){ref-type="fig"}). To establish whether binding of CTCF to Y^wt^is inhibited by cytosine methylation, we tested Y^wt^105-bp immobilized templates after *in vitro*methylation of cytosine residues by CpG methyltransferase M.Sssl. For comparison, we examined CTCF motifs containing a higher CpG content, including site A of the MYC gene \[[@B32]\] as well as the B1 sequence of the ICR of the human *IGF2*/*H19*locus \[[@B10]\]. Cytosine methylation at the human B1 sequence is known to inhibit binding of CTCF. Consistent with this, recruitment of CTCF *in vitro*to immobilized templates containing the B1 sequence or the MYC site A is highly sensitive to DNA methylation (Figure [4B](#F4){ref-type="fig"}, top). In contrast, CpG methylation of the Y^wt^motif has no effect on CTCF recruitment. Replacement of the Y^wt^core motif by the CTCF-binding sites of the chicken FII insulator element yields similar results. However, CTCF binding becomes sensitive to CpG methylation upon modification of the core motif to the mouse R3 sequence, a homologue of the human B1 sequence. In combination, despite the presence of a methylable CpG residue, binding of CTCF to the Y^wt^sequence of the *IGF2BP1*gene *in vitro*is not sensitive to CpG methylation.

![**Cytosine methylation of the CTCF core motif Y does not influence binding of CTCF**. **(A)**CTCF motifs used in the context of the 105-bp immobilized template derived from the intronic region of the *IGF2BP1*gene are shown. The position frequency matrix of the CTCF target motif is shown at the top. Only the sense strand of the motifs is shown. CpG residues are indicated by filled black circles. Myc-A, IGF2 huB1 and Y^wt^are CTCF target sequences derived from *MYC*, *IGF2*and *IGF2BP1*gene loci. Y^mut^chFII and Y^mut^mmR3 contain the CTCF target sequence of the chicken HS4 insulator \[[@B57]\] and the CTCF target region of the mouse imprinting control region R3 \[[@B10]\]. **(B)**Top: control experiments revealed the sensitivity of CTCF binding to DNA methylation (CpG me) at the myc-A and IGF2 huB1 templates. Bottom: methylation of the 105-bp Y^wt^template did not affect the recruitment of CTCF. While methylated chicken FII CTCF target sites efficiently recruited CTCF, CpG methylation of the mouse R3 sequence decreased the binding of CTCF.](1756-8935-4-14-4){#F4}

To confirm that our *in vitro*characterization of CTCF binding accurately reflected the *in vivo*association of CTCF with the *IGF2BP1*locus, we evaluated the methylation status of the CTCF motif and adjacent CpG residues in the *IGF2BP1*intronic region in both biallelically (GM7057) and monoallelically (GM6989) expressing cells by using bisulfite sequencing (Figure [5](#F5){ref-type="fig"}). The methylation levels were calculated using BiQ Analyzer software \[[@B33]\]. Our data reveal that the CpG residue at the 5\' end of the CTCF binding motif Y is invariably methylated. In addition, other methylable residues in this region exhibited some degree of DNA methylation. To further confirm binding of CTCF to methylated *IGF2BP1*intronic sequences, we bisulfite-sequenced DNA derived from immunoprecipitates of ChIP experiments with CTCF antibodies. As a control, we bisulfite-sequenced the *IGF2BP1*region derived from anti-H3K9me3 ChIP experiments. The results confirmed our *in vitro*finding that demonstrated an association of CTCF with a methylated motif (Figures [5B](#F5){ref-type="fig"} and [5C](#F5){ref-type="fig"}).

![**DNA methylation analysis of the *IGF2BP1*CTCF binding region**. Analysis of DNA methylation with bisulfite sequencing at the intronic CTCF binding region of the *IGF2BP1*gene is shown. **(A)**The percentage of methylation of CpG sites in gDNA derived from cell lines that express *IGF2BP1*from only one allele (GM7016, GM6989) or from both alleles (GM7057) is shown. The CpG residue located within the CTCF binding motif is invariably methylated and is indicated by the thick black bar located adjacent to CpG site 7 (indicated by asterisks). **(B)**The percentage of methylation at each CpG site of the *IGF2BP1*CTCF site in DNA samples recovered from anti-H3K9me3 ChIP. **(C)**The percentage of methylation at each CpG site of the *IGF2BP1*CTCF site in DNA samples recovered from anti-CTCF ChIP experiments. The level of DNA methylation is represented according to the heat map keys located at the bottom of the figure.](1756-8935-4-14-5){#F5}

CTCF and H3K9me3 colocalize at both the maternal and paternal *IGF2BP1*alleles
------------------------------------------------------------------------------

Consistent methylation of the CTCF-binding motif in *IGF2BP1*indicated that DNA methylation is not allele-specific. To directly determine whether CTCF is bound monoallelically, we determined the allele-specific association of both CTCF and H3K9me3 by sequencing DNA recovered from ChIP experiments. We first identified informative cell lines by genotyping individuals from CEPH pedigree 1331 at SNP sites located close to the CTCF binding site. Cell lines derived from both monoallelically (GM7016 and GM6989) and biallelically (GM7057) expressing individuals were heterozygous at SNP site rs11870560 at the CTCF site (Figure [6A](#F6){ref-type="fig"}). We first applied the allelic discrimination assay to serial dilutions of known homozygotes of the two possible alleles to test its ability to quantitatively assess the contribution of each allele in a DNA mixture. This assay provides quantitative results with high sensitivity and reproducibility within a ten-fold range of DNA concentrations, thus making it a useful tool for allelic discrimination of immunoprecipitated DNA (Figure S4 in Additional file [2](#S2){ref-type="supplementary-material"}). We used two monoallelically (GM7016 and GM6989) and one biallelically (GM7057) expressing cell lines to genotype DNA recovered from ChIP assays using either anti-CTCF or anti-H3K9me3 antibodies. Each analysis was performed in triplicate. Equal proportions of the two sequence variants were detected in DNA derived from ChIP assays with either H3K9me3 or CTCF antibodies, indicating that CTCF associates with both the maternal and paternal alleles (Figure [6B](#F6){ref-type="fig"}). Thus, monoallelic expression of the *IGF2BP1*gene is not mediated through monoallelic binding of CTCF.

![**Allelic specificity of CTCF and H3K9me3**. Informative ChIP templates were analyzed using the TaqMan allelic discrimination assay to address the allelic association of CTCF and H3K9me3. **(A)**Genotyping results at rs11870560 identify informative cell lines useful for the detection of allele-specific association of CTCF and H3K9me3. gDNA obtained from monoallelic and biallelic cell lines were genotyped using the TaqMan allelic discrimination assay. Squares represent gDNA samples and are coded in red and green to represent cell lines that are homozygous for allele C and allele T, respectively. Orange indicates heterozygous individuals. Averaged triplicate of a no-template control (NTC) is shown near the origin of the graph. **(B)**Genotyping at SNP rs11870560 with DNA templates recovered from ChIP experiments was used to identify the enrichment of the two alleles with either CTCF (circle) or H3K9me3 (triangle). Each color shown in the figure key represents a lymphoblastoid cell line (LCL) derived from an individual of the pedigree, while the shape represents the source of each sample (for example, squares signify input samples, while circles and triangles indicate ChIP samples obtained with CTCF and H3K9me3 antibodies, respectively). Immunoprecipitated templates were generated using the ChIP protocol described in Materials and Methods. Both monoallelic and biallelic cell lines indicate biallelic distribution of both CTCF and H3K9me3. Diamonds indicate control LCL samples (standards) previously genotyped as homozygous CC, heterozygous CT and homozygous TT.](1756-8935-4-14-6){#F6}

The *IGF2BP1*promoter associates with both active and silent histone modifications in B cells
---------------------------------------------------------------------------------------------

To define alternative mechanisms responsible for random monoallelic expression of *IGF2BP1*, we sought to identify markers that distinguish the active and inactive alleles. K27-trimethylated and K4-trimethylated histone H3, respectively, mark transcriptionally silent and active chromatin. We determined the relative enrichment of these two histone markers at the *IGF2BP1*promoter for each allele in both monoallelically and biallelically expressing cell lines using ChIP with anti-H3K4me3 and anti-H3K27me3 antibodies. Both H3K4me3 and H3K27me3 were detected at the *IGF2BP1*gene promoter (Figure [7A](#F7){ref-type="fig"}). To determine whether any of the histone modifications selectively associates with either allele, we again searched for informative sequence SNPs at the *IGF2BP1*promoter region in the CEPH pedigree. Cell lines derived from individuals GM6989 (monoallelically expressing cell line) and 7057 (biallelically expressing cell line) were heterozygous at SNP rs9890278 located upstream of the transcription initiation site, whereas GM7007 (monoallelically expressing cell line) was heterozygous for SNP rs4794017 located 1 kb downstream of the transcription initiation site. To address whether active and silent alleles in these cell lines are distinguished by specific histone markers, we sequenced SNPs rs9890278 and rs4794017 in gDNA recovered from ChIP experiments using anti-H3K4me3 and anti-H3K27me3 antibodies. The results revealed that both H3K4me3 and H3K27me3 are detected on both alleles in a bivalent fashion (Figure [7](#F7){ref-type="fig"}). In combination, our results indicate that both active and silent histone markers (H3K4me3 and H3K27me3) coexist in the promoter region of both *IGF2BP1*alleles in monoallelically as well as biallelically expressing cell lines. These data indicate that allele-specific expression of *IGF2BP1*cannot be explained by differential association of active and silent histone markers.

![***IGF2BP1*promoter region is enriched with activating and silencing chromatin modifications**. DNA recovered from ChIP experiments using anti-H3K4me3, anti-H3K27me3 and RNA polymerase II ChIP templates was genotyped by sequencing the *IGF2BP1*promoter region containing sequence variant rs4794017 or rs9890278. Left: Enrichment of H3K4me3 (K4) and H3K27me3 (K27) in monoallelically (GM7007, GM6989), and biallelically (GM7057) expressing cell lines. The positions of informative SNPs rs479017 and rs9890278 are shown in Figure 1. Both activating and silencing marks are significantly enriched. Right: Sequences enriched by ChIP were excised and sequenced. The results show an association of both alleles with active and silent histone modifications at the *IGF2BP1*promoter region independent of transcriptional status.](1756-8935-4-14-7){#F7}

Silencing of the inactive *IGF2BP1*allele by inhibition of RNA polymerase II elongation
---------------------------------------------------------------------------------------

Monoallelic expression of *IGF2BP1*cannot be attributed solely to selective activation or silencing of one allele through histone modifications, since H3K4me3 as well as H3K27me3 are detected at both alleles. H3K4me3 is typically associated with transcriptionally active alleles, raising the question whether allele-specific transcription elongation or RNA processing accounts for monoallelic expression of the *IGF2BP1*gene. To address this hypothesis, we again searched mono- and biallelically expressing cell lines for sequence SNPs near the site of transcription initiation at the *IGF2BP1*promoter. Within CEPH pedigree 1331, only line GM7007 contained a heterozygous genotype at SNP site rs4794017 located within intron 1, 1 kb downstream of the transcription initiation site. We performed RNA polymerase II ChIP on chromatin prepared from this monoallelically expressing line. Quantitative real-time PCR analyses revealed enrichment of *IGF2BP1*promoter sequences similar to the enrichment observed at the MYC promoter. Immunoprecipitated DNA was PCR-amplified and sequenced (Figure [8A](#F8){ref-type="fig"}). Identification of both sequence variants at rs4794017 in DNA recovered from ChIP experiments indicates that RNA polymerase II is associated with both *IGF2BP1*alleles, which is consistent with the presence of H3K4me3 at the promoter of both alleles.

![**RNA polymerase II associates with both alleles in a monoallelically expressing cell line**. **(A)**Recruitment of RNA polymerase II to the *IGF2BP1*promoter was examined by ChIP in monoallelically expressing GM7007 cells. DNA recovered from chromatin that had been immunoprecipitated with anti-RNA polymerase II antibodies (Pol2) was amplified and sequenced for allelic association. Sequencing results (bottom) reveal that both alleles of the monoallelically expressing cell line GM7007 associate with RNA polymerase II near SNP site rs4794017. In contrast, sequencing of DNA from \"no antibody\" ChIP reactions failed to produce sequence reads. **(B)**Allele specificity of precursor mRNA was determined by sequencing of cDNA prepared from total RNA of GM7007 cells. RNA had been extensively pretreated with DNase I to eliminate gDNA prior to reverse transcription by RT. Subsequently, cDNA samples were amplified using primers flanking rs4794017. In the absence of RT (-RT), no amplification products were oberved. +RT amplicons were gel-purified and sequenced. Bottom: Sequence traces at the heterozygous SNP site rs4794017 located 1 kb downstream of the transcription initiation site in cDNA of GM7007 indicate a single allele.](1756-8935-4-14-8){#F8}

These data suggest that allele specificity of transcription is achieved after recruitment of RNA polymerase to both alleles, such as through transcriptional pausing and/or selective RNA processing. A major rate-limiting step in transcription elongation is pausing of RNA polymerase II in the promoter proximal region immediately downstream of the transcription initiation site \[[@B34]-[@B37]\]. We sequenced the 5\' portion of the *IGF2BP1*gene of all monoallelically expressing cell lines to identify sequence variants that would be useful for allelic identification of promoter proximal regions occupied by RNA polymerase II or for the determination of the allelic origin of unspliced, precursor pre-mRNA transcripts. Since no additional informative sequence variants were identified, we focused on the detection and sequencing of pre-mRNA transcripts about 1 kb downstream of the transcription initiation site in GM7007. Using the informative SNPs located within intron 1 of this gene, we targeted nascent unspliced RNA with primers designed to amplify a region containing SNP site rs4794017. To avoid detection of gDNA in RNA samples, DNA was efficiently removed by treatment with an engineered, highly active form of DNase I (TURBO DNase I; Applied Biosystems/Ambion, Austin, TX, USA). This protocol allowed detection of pre-mRNA free of gDNA contamination (Figure [8B](#F8){ref-type="fig"}). Sequencing of amplified *IGF2BP1*pre-cDNA revealed only one of the two sequence variants at SNP rs4794017, indicating that pre-mRNA transcripts are transcribed from only one allele despite the presence of RNA polymerase II on both alleles. Thus, our data indicate that monoallelic expression of the *IGF2BP1*gene is regulated through allele-specific transcriptional elongation prior to SNP site rs4794017, located approximately 600 bp downstream of the first intron splice site.

Discussion
==========

Allele-specific expression in which one parental allele is stochastically or parent-of-origin-specifically silenced is widespread in mammalian organisms. Large-scale, allele-specific gene expression analyses have revealed that 5% to 10% of autosomal genes show random monoallelic transcription \[[@B7]\]. The stability of allele-specific expression through many cell passages suggests that epigenetic modifications maintain this specific type of gene regulation throughout generations of cells. Analogously to the regulation at the imprinted *IGF2*/*H19*locus, we tested the hypothesis whether monoallelic binding of CTCF, a characteristic marker for the *IGF2*/*H19*ICR, also underlies random monoallelic expression. Using ChIP-chip analyses, we identified chromosomal loci that are enriched in both CTCF and H3K9me3 and cross-correlated their positions with previously published lists of monoallelically expressed genes. Our data indicate that genomic loci enriched for both CTCF and H3K9me3 do not significantly correlate with monoallelically expressed genes. While this lack of correlation could be formally attributed to variations in monoallelic expression between different cell lines and types, it should be noted that the genome-wide pattern of CTCF binding is very consistent between different cell lineages \[[@B30],[@B38],[@B39]\]. Thus, if CTCF and H3K9me3 contribute to allele-specific expression, it should be detectable through allele-specific association of CTCF and H3K9me3. Focusing on the *IGF2BP1*gene, we tested whether monoallelic expression in a pedigree of LCLs correlates with monoallelic binding of CTCF. Although binding of CTCF to its targets is thought to be sensitive to DNA methylation, we surprisingly found the cytosine residue closely flanking the CTCF target motif at the *IGF2BP1*gene to be consistently methylated without any effect on CTCF recruitment. Indeed, our *in vitro*analyses of the binding requirements using immobilized templates confirmed that methylation of cytosine residues within the *IGF2BP1*sequence does not affect CTCF binding. These data are consistent with those in previous studies in which researchers found that cytosine methylation outside the CTCF core motif did not affect the binding affinity of bacterially expressed wild-type and mutant CTCF proteins \[[@B40]\]. This information is useful for the identification of the genomic subset of CTCF sites that might contribute to differential cell- and stage-specific expression due to their sensitivity to cytosine methylation, potentially mediating changes in large-scale chromatin organization during development and disease.

A number of studies have examined the correlation of allele-specific expression with allele-specific association of epigenetic markers \[[@B21],[@B41]-[@B45]\]. The data produced by these studies have established common signatures of imprinted alleles, including H3K9me3 and H3K4me3, providing a powerful means by which to identify novel imprinted or monoallelically expressed loci \[[@B46]-[@B48]\]. In contrast to the strict allele-specific association of DNA methylation and chromatin markers at imprinted genes, histone modifications at the nonimprinted, monoallelically expressed *IGF2BP1*gene do not predict the active allele. Both H3K4me3 and H3K27me3, markers characteristic of active and inactive loci, are associated with each allele, as both sequence variants of SNP rs4794017 are present in the DNA of heterozygous individuals recovered from ChIP experiments. Moreover, loading of RNA polymerase II also does not provide a reliable marker for identifying the transcribed allele. Our ChIP experiments identified both sequence variants at SNP rs4794017 within the promoter proximal region of anti-RNA polymerase II immunoprecipitated DNA. Because only one LCL in our study was informative for determining an association of RNA polymerase II at the *IGF2BP1*alleles, we could not define how frequently this type of regulation occurs within cell lineages and throughout the genome. However, other investigators have reported similar results at the *PCNA*gene. Maynard *et al*. \[[@B44]\] found that both *PCNA*alleles in IMR90 cells are bound by RNA polymerase II, although only one allele generates full-length mRNA. Together, these data suggest that transcription elongation not only is a general rate-limiting step in the transcription of the vast majority of genes \[[@B34],[@B35],[@B37]\] but also regulates the expression of a subset of monoallelically expressed genes.

The expression of *IGF2BP1*in differentiated cell types, including LCLs, is significantly lower than in embryonic stem cells. In an attempt to determine whether allele-specific expression also contributes to *IGF2BP1*regulation early in development, we genotyped both gDNA and cDNA in 11 human embryonic stem cell (hESC) lines. However, while only three hESC lines were informative (heterozygous at SNP rs11655950), all three expressed *IGF2BP1*in a biallelic manner. Although the number of available and informative hESC lines is not sufficient to clearly define a role for allele-specific elongation in early developmental stages, we believe that it is unlikely that this mechanism is restricted to cell types with low levels of *IGF2BP1*expression. Control of transcriptional activity through promoter proximal pausing or premature termination of transcription is not restricted to specific gene classes characterized by low levels of transcriptional activity \[[@B35]\]. We speculate that distinct positioning of the homologous alleles within the nuclear space and association with distinct \"transcription factories\" may contribute to monoallelic transcription elongation.

The *IGF2BP1*gene is highly expressed during embryonic development and is required for the regulation of mRNA stability of several genes involved in growth regulation, including the *IGF2*, β-catenin and *MYC*genes \[[@B23]-[@B25]\]. Consistent with its role in early developmental stages, the *IGF2BP1*gene is downregulated in differentiated cell types, and overexpression of *IGF2BP1*is known to occur in multiple human cancers, including breast, lung and colon \[[@B49]-[@B52]\]. Thus, changes in the level of *IGF2BP1*expression through silencing of only one allele could provide a safeguard against pathogenesis and disease.

Conclusions
===========

Allele-specific gene expression is common in the human genome and is thought to contribute to phenotypic variation. The allele-specific association of CTCF, H3K9me3 and DNA methylation is a characteristic marker of imprinted gene expression at the *IGF2*/*H19*locus, raising the question whether these epigenetic markers are useful for identifying both imprinted and random monoallelically expressed genes throughout the genome. In this study, we have demonstrated that colocalization of CTCF and H3K9me3 does not represent a reliable chromatin signature indicative of monoallelic expression. In addition, we conclude that allele-specific binding of CTCF requires methylation of very specific cytosine residues within the target motif, effectively limiting the number of CTCF binding sites potentially affected by allele-specific binding. In addition, the active and inactive alleles of random monoallelically expressed genes do not necessarily correlate with active or inactive histone markers. Remarkably, the selection of individual alleles for expression at the *IGF2BP1*locus occurs during early stages of transcription elongation.

Methods
=======

ChIP-chip analyses
------------------

The amplification and preparation of immunoprecipitated DNA derived from HBL100 cells for hybridization to ENCODE arrays (Roche NimbleGen Inc., Madison, WI, USA) was performed essentially as described previously \[[@B53]\]. Sample labeling and array hybridization were performed at NimbleGen Systems Inc. Genomic control DNA was labeled with Cy3, and sample DNA was labeled with Cy5. Both Cy3- and Cy5-labeled DNA were hybridized to high-density arrays tiling through ENCODE regions with 50-mer oligonucleotides across nonrepetitive genomic regions. The ratios of the Cy3 and Cy5 intensities of each probe were calculated using NimbleGen Systems\' proprietary software.

Peak detection and false-positive rate calculation
--------------------------------------------------

A genomic sequence was considered a possible CTCF-binding site if there were at least four probes among the sequence probe and the flanking probes within a window covering 250 bp on both sides of the probe had log~2~ratio values above a specified cutoff value. The cutoff value was calculated separately for each chromosome. The cutoff value is a given percentage of the value (mean + 6 × standard deviation) of the log~2~ratio values of all the probes covering the chromosome. The possible binding sites thus detected are called peaks. To calculate the false-positive rate (FPR) by data permutation, the log~2~ratio values among probes were scrambled to generate a randomized data set for each individual chromosome. Multiple repetitions of this process generated 20 randomized data sets for each chromosome. Subsequently, the peak detection algorithm described above was applied to count the average number of peaks in the 20 randomized data sets using the same cutoff. The ratio of that number to the number of peaks from the nonrandomized data set is the FPR. The FPR is associated with the threshold setting, which is indicated by the value of cutoff *P*. Peak detection and randomization of data sets were repeated for different threshold settings of *P*. The corresponding FPRs were calculated and assigned to peaks. The FPR value assigned to the individual peaks is the value associated with the cutoff *P*at which the peak is first detected.

Peak discovery was performed using chromatin immunoprecipitate:input ratios combined from adjacent oligonucleotides within 250-bp regions. The FPR of detection was estimated by permutation analyses in which the experimentally determined log~2~ratio values were reassigned to probes in a random fashion, allowing selection of stringency and specificity levels. To define sites of CTCF interaction with high confidence, peaks were required to be present in all three biological replicates and to be generated at a FPR \< 0.05.

Chromatin immunoprecipitation
-----------------------------

Chromatin was prepared for immunoprecipitation as described previously \[[@B54]\] by cross-linking the cells in 1% formaldehyde for 5 minutes and subjecting them to subsequent sonication until the bulk of DNA was 300 to 600 bp in size. Chromatin corresponding to 2 × 10^7^cells was immunoprecipitated with anti-CTCF antibody (D31H2; Cell Signaling Technology, Danvers, MA, USA), anti-H3K9me3 antibody (ab8898; Abcam, Cambridge, MA, USA), anti-trimethyl K4-histone H3 antibody (ab8580; Abcam), anti-trimethyl K27-histone H3 antibody (Millipore 07-449, Billerica MA, USA) or anti-RNA polymerase II antibody (sc899; Santa Cruz Biotechnology, Santa Cruz, CA, USA). Immunoprecipitates were washed, the DNA protein cross-links were reversed and the recovered DNA was tested by performing conventional quantitative PCR as described previously \[[@B54]\]. RNA polymerase II ChIP experiments were performed using the Matrix ChIP protocol \[[@B55]\]. Sequences of primers specific for the gene loci under study as well as the reference primers are available upon request.

RNA extraction and RT-PCR
-------------------------

Synthesis of cDNA was carried out according to the manufacturer\'s instructions (Qiagen, Valencia, CA, USA) using 1 μg of total RNA. For detection of pre-mRNA, RNA preparations were pretreated with TURBO DNase I (Ambion/Applied Biosystems) as described in the manufacturer\'s protocol. RT was carried out at 37°C for one hour.

Cell culture
------------

Cell lines were cultured in RPMI 1640 medium supplemented with 10% FCS, 2 mM L-glutamine and the antibiotics penicillin (50 U/mL) and streptomycin.

Sodium bisulfite conversions
----------------------------

gDNA was treated with sodium bisulfite using the EZ DNA Methylation Kit (Zymo Research, Orange, CA, USA) according to the manufacturer\'s instructions. PCR amplification of bisulfite-treated DNA was performed using ZymoTaq DNA Polymerase (Zymo Research Corporation, Irvine, CA, USA) and conversion-specific primers targeted to the *IGF2BP1*CTCF region (forward primer: 5\'-TATTTTTTAGTTGGGTTAAT-TGGTG-3\', reverse primer: 5\'-ATACTACCTCTCCTTCCAAAATCTC-3\'). The amplified products were purified by gel electrophoresis and sequenced. Each case was scored as methylated or unmethylated, and the percentage of methylation was calculated using BiQ Analyzer software \[[@B33]\].

TaqMan allelic discrimination assays
------------------------------------

TaqMan allelic discrimination assays were performed according to the manufacturer\'s instructions with the following adjustments: cDNA from B lymphoblasts was preamplified for 14 cycles. PCR products were gel-purified and subsequently used as templates in the genotyping of samples. The specific primer sequences used are avaliable upon request.

*In vitro*CTCF binding analysis using immobilized templates
-----------------------------------------------------------

Crude nuclear extract was prepared from 1 × 10^9^Jurkat cells grown in growth media (RPMI 1640 with 10% fetal bovine serum) according to methods described previously \[[@B56]\]. Biotinylated template DNA was generated by PCR amplification of the *IGF2BP1*intronic region using a biotinylated/nonbiotinylated primer combination. The specific primer sequences are available upon request. For each binding reaction, 1 pM biotinylated DNA template was coupled to 50-μg streptavidin-linked magnetic beads (Dynabeads M-280 Streptavidin; Invitrogen, Carlsbad, CA, USA). Templates immobilized to magnetic beads were washed three times in B&W buffer (5 mM Tris, pH 7.5, 0.5 mM ethylenediaminetetraacetic acid (EDTA), 1 M NaCl) and resuspended in Jurkat nuclear extract. After a two-hour incubation at 4°C, immobilized templates were washed three times in Dignam buffer D (20 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, pH 7.9, 20% glycerol, 0.1 M KCl, 1 mM EDTA, 0.1 mM ethylene glycol tetraacetic acid, 1% Nonidet P-40, 1 mM dithiothreitol) containing protease inhibitor (P8340; Sigma, St Louis, MO, USA). To recover template-bound proteins, beads were incubated in elution buffer (5 mM Tris, pH 7.5, 0.5 mM EDTA, 1 M NaHCO~3~) including protease inhibitors. After a 5-minute incubation, the eluate was removed and transferred into a fresh tube. The presence of CTCF in the eluate was determined using standard Western blot analysis protocols.
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**Table S1. Genomic coordinates of 293 genomic sites that are marked by both CTCF and H2K9me3**. Table S2. List of genes tested for monoallelic expression in lymphoblastoid cell lines.
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###### Additional file 2

**Figure S1. Detection and colocalization of CTCF and H3K9me3 at the human IGF2-H19 ICR locus by ChIP-[c]{.ul}hip experiments**. Top: Enrichment of CTCF binding sites. Middle: Results of large-scale array-based chromatin immunoprecipitation (ChIP-chip) survey of histone H3 trimethylated at lysine 9 (H3K9me3) binding. Bottom: H19 exons demonstrating positions of CTCF binding and histone modifications relative to exons. **Figure S2. Analysis of the clonal status of lymphoblastoid cell lines used in this study**. Following the protocol described in \[[@B22]\], PCR amplification of two regions within the variable segment in the immunoglobulin heavy chain gene (conserved framework region 2 (Fr2) and the variable joining regions (VLJH)) reveals the clonal status of lymphoblastoid cell lines (LCLs). The amplification product from a polyclonal population (P) gives rise to fragments of varying length due to the large number of rearranged immunoglobulin genes and appears as a broad band. Amplification of DNA derived from monoclonal cell lines results in one or two discrete bands within an expected size range of 240 to 280 bp. The polyclonal sample (P) was obtained from the peripheral blood of a healthy donor. Lanes 1 through 4: monoclonal cell lines GM7007, GM7033, GM6989 and GM7030. Lanes 5 through 8: monoclonal lines GM7050, GM7023, GM7059 and GM7057. MW, DNA size marker. **Figure S3. Sequencing results give results identical to those derived from the TaqMan allelic discrimination assay**. **(A)**Standard sequencing results of two individuals at SNP site rs9904288. **(B)**TaqMan allelic discrimination assay confirms the heterozygosity of GM7057 and the homozygosity of GM6990. **Figure S4. Quantitative assessment of TaqMan genotyping using specific probe set at SNP rs11655950**. The 3\'-UTR of the *IGF2BP1*gene was amplified using primers given in Supplemental Table 2. This segment contains an A/G SNP. The PCRs included a FAM-labeled probe for the A allele and a VIC-labeled probe for the B allele. After PCR amplification, an end point fluorescence reading was taken on the ABI PRISM 7700 with SDS version 1.4 software (Applied Biosystems). The determination of the quantitative assignment of known genotypes is plotted. Concentration dilutions were created using known homozygous cell lines. Preparations of gDNA samples shown represent the following allele B/allele A ratios: 100:0, 80:20, 60:40, 50:50, 40:20, 20:80 and 0:100. Heterozygosity was based on the fluorescence intensity of FAM, VIC or both dyes together. Error bars indicate 5% of triplicate sample value. Allele A curve yields *y*= 0.0102*x*+ 0.0415 with *R*^2^= 0.98934. Allele B curve yields *y*= -0.0085*x*+ 0.9796 with *R*^2^= 0.98196. **Figure S5. Phylogenetic tree of motifs determined from motif analysis of the 8,462 loci derived from the ChIP-chip analysis using STAMP**. All members of the highlighted group have matches identical to the canonical CTCF motif model as part of the JASPAR transcription factor binding site database. The resulting familial binding profile for all 68 such models is displayed. **Figure S6. Fine mapping of CTCF motifs in sequences enriched in ChIP-chip experiments**. Motif reads were mapped onto the genomic loci defined by ChIP-chip for CTCF binding. The extent of the ChIP-enriched sequences is indicated by red bar. Several read clusters are apparent and vary in depth and spatial extent (green areas). **Figure S7. Frequency distribution of cluster depth for all motif clusters**. A power law is apparent for clusters of depth ≤ 10 with evident deviation in the population and a maximum of about 40. The vertical green line demarcates the low and high confidence clusters. **Figure S8. Discrimination between high- and low-confidence sites**. The region shown in Supplemental Figure S6 is annotated by overlaying enriched sequences with high- and low-confidence tracks. **Figure S9. Sequences of immobilized templates used in *in vitro*binding experiments**. CTCF core motifs Y and Z are underlined. Site-specific mutations in either the Y or Z motif are highlighted in yellow. In Y^mut^chFII and Y^mut^mmR3, site-specific mutations (highlighted in green) were introduced to generate CTCF motifs identical to the chicken HS4 FII site and the mouse imprinting control region R3. The *IGF2*wild-type huB1 sequence is derived from the human *IGF2*imprinting control region containing the methylation-sensitive CTCF binding site B1.
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